This compound is a pharmaceutical intermediate specifically used in the manufacturing of impurities related to afatinib. It features a complex quinazoline core with multiple functional groups including aromatic rings, ether linkages, and an amide bond, reflecting its role in advanced organic synthesis for pharmaceutical development.
Alcance del contenido: La información de esta página se refiere a la identificación química y a los contextos de suministro industrial, investigación y producción. No constituye una afirmación terapéutica, un consejo médico ni instrucciones de uso de medicamentos.
¿Adquiriendo o suministrando este compuesto?
Publique su inventario o una solicitud de compra
CAS 2413212-23-2
N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(((S)-tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-3,4-bis(dimethylamino)butanamide
Pharmaceutical reference impurity standard
(S)-N1-(4-((3-CHLORO-4-FLUOROPHENYL)AMINO)-7-((TETRAHYDROFURAN-3-YL)OXY)QUINAZOLIN-6-YL)-N2,N2-DIMETHYLOXALAMIDE
pharmaceutical intermediate
N-(3,4-Difluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine
Pharmaceutical intermediate for afatinib impurities
Afatinib Impurity 18
Pharmaceutical impurity reference standard
(S,E)-2-((3-Chloro-4-fluorophenyl)(6-(4-(dimethylamino)but-2-enamido)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-4-yl)amino)malonic acid
Pharmaceutical intermediate for Afatinib impurities
2306254-34-0free base
pharmaceutical intermediate
(4,5,6,7-Tetrahydropyrazolo[1,5-a]pyrazin-2-yl)methanol dihydrochloride
Pharmaceutical intermediate
Afatinib Impurity AFT-8
Active pharmaceutical ingredient impurity reference
(3R)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3R)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)-3-hydroxybutanamide
IQINQKMQCQYKAD-HZPDHXFCSA-N
CN(C)C[C@@H](CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)O[C@@H]4CCOC4)O
—